Table 1– Results of univariate and multivariate logistic regression analyses assessing the eligibility to receive erlotinib as second-line therapy (L2) according to baseline patient characteristics (prior to induction therapy)

	Patients receiving L2 n (%)	Univariate analysis^#		Multivariate analysis^¶
		OR (95% CI)	p-value	OR (95% CI)	p-value
Treatment arm
Doublet chemotherapy	144 (64.3)	1.14 (0.77–1.69)	0.5073
Monotherapy	148 (67.3)	1
Sex
Male	210 (64.4)	1
Female	82 (69.5)	1.26 (0.80–1.98)	0.3201
Age years
≤80	217 (65.4)	0.93 (0.59–1.47)	0.7572
>80	75 (67.0)	1
Performance status⁺
0–1	234 (72.9)	2.97 (1.93–4.57)	<0.0001	2.45 (1.55–3.88)	0.0001
2^§	58 (47.6)	1		1
Stage
IIIA–IIIB	47 (56.0)	1
IV	245 (68.1)	1.67 (1.03–2.72)	0.0364	1.67 (1.00–2.79)	0.0497
Histology
Squamous or other	142 (65.1)	1
Adenocarcinoma	150 (66.4)	1.06 (0.71–1.56)	0.7841
Smoking status
Never smoked	68 (72.3)	1.47 (0.89–2.43)	0.1317
Ever smoked	224 (64.0)	1
MMS examination
≤23	34 (52.3)	1
>23	250 (67.8)	1.92 (1.12–3.27)	0.0169
ADL score
<6	42 (48.8)	1
6	239 (69.7)	2.41 (1.49–3.90)	0.0003	1.82 (1.08–3.05)	0.0242
CCI
≤2	226 (67.7)	1.40 (0.89–2.18)	0.1426
>2	66 (60.0)	1
BMI kg·m⁻²
≤20	32 (61.5)	1
20 to ≤26	156 (63.7)	1.10 (0.59–2.03)	0.7718
>26 to ≤30	70 (72.2)	1.62 (0.79–3.31)	0.1850
>30	34 (68.0)	1.33 (0.59–3.00)	0.4953
Weight loss before randomisation %
≤5	144 (72.4)	1.73 (1.15–2.59)	0.0081
>5	144 (60.3)	1

MMS: mini-mental state; ADL: activities of daily living questionnaire; CCI: Charlson’s comorbidity index; BMI: body mass index. ^#: n=444; ^¶: n=421; ⁺: six patients who had not received L2 had an initial World Health Organization performance status of 3; ^§: patients who completed first-line therapy.